Press releases 28th August 2017

U.S. Cycling Athlete, Kayle LeoGrande, Receives Sanction for Second ADRV

USADA announced today that Kayle LeoGrande, of Upland, Calif., an athlete in the sport of cycling, has received an eight-year sanction for his second anti-doping rule violation after testing positive for seven prohibited substances. LeoGrande was selected to submit a sample as a result of being among the top finishers in his event at the 2017 Dana Point Grand Prix of Cycling in Dana Point, Calif.

LeoGrande was subject to testing because the event was sanctioned by USA Cycling, which maintains the RaceClean Program that works to fight doping at the amateur level of cycling. The goal of the RaceClean Program is to increase testing and education at the amateur level to provide greater doping deterrence, and this USA Cycling program is executed through member funding, donations, and local association partnerships.

LeoGrande, 40, tested positive for raloxifene, ostarine, ibutamoren, GW1516 sulfone, RAD140, LGD4033, and andarine as the result of an in‐competition urine sample he provided on April 30, 2017. Raloxifene and GW1516 sulfone, a metabolite of GW1516, are prohibited substances in the class of Hormone and Metabolic Modulators; ostarine, RAD140, LGD4033 and andarine, are prohibited substances in the class of Anabolic Agents; and ibutamoren is a prohibited substance in the class of Peptide Hormones, Growth Factors, Related Substances and Mimetics. These substances are prohibited at all times under the USADA Protocol for Olympic and Paralympic Movement Testing, the United States Olympic Committee National Anti-Doping Policies, and the International Cycling Union Anti-Doping Rules, all of which have adopted the World Anti-Doping Code and the World Anti-Doping Agency Prohibited List.

LeoGrande’s first anti-doping rule violation resulted from his use of the prohibited substance erythropoietin (EPO) while competing in The Point Premium Root Beer International Cycling Classic in 2007, which USADA established through witness testimony and other evidence presented during a multi-day hearing before a three-person, independent panel of arbitrators. At the conclusion of LeoGrande’s first period of ineligibility imposed by the arbitrators, he also admitted he had knowingly used EPO in violation of the rules. Following his most recent positive test from the Dana Point Grand Prix of Cycling, LeoGrande did not request a hearing to contest the charges against him.

LeoGrande’s eight-year period of ineligibility began on May 25, 2017, the date he accepted a provisional suspension. In addition, LeoGrande has been disqualified from all competitive results obtained on and subsequent to April 30, 2017, including forfeiture of any medals, points and prizes.

• This media release was originally published by the US Anti-Doping Agency (USADA) on 28 August 2017. To access the original, please click here.

You may also like...

Pin It on Pinterest

Share This